ML-016 in Advanced Cancer With Lung and/or Liver Involvement

This is an open-label, multi-center, phase 1/2 dose-escalation and dose expansion study evaluating the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of ML-016 in participants with advanced solid tumors with lung and/or liver involvement (primary or metastatic disease).

Trial Details

NCT ID
NCT07723482
Phase
PHASE1 / PHASE2
Sponsor
BrYet US, Inc.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • ML-016
Locations (sample)
  • Miranda, New South Wales, Australia|-34.03857,151.10005
  • Wollongong, New South Wales, Australia|-34.424,150.89345
  • Buderim, Queensland, Australia|-26.68443,153.05705

Key Eligibility Criteria

  • Age ≥18 years old on the day of signing the consent form
  • Histopathological or cytological confirmed diagnosis of advanced (locally advanced or metastatic) solid malignancy which is refractory to standard …
  • Eastern Cooperative Oncology Group Performance Status ≤1
  • The participant has adequate baseline hematologic function, as demonstrated by the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →